亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)—NRG-GI004/SWOG-S1610.

医学 内科学 临床终点 肿瘤科 结直肠癌 福克斯 贝伐单抗 微卫星不稳定性 DNA错配修复 奥沙利铂 癌症 阿替唑单抗 彭布罗利珠单抗 临床研究阶段 化疗 临床试验 免疫疗法
作者
Michael J. Overman,Greg Yothers,Samuel A. Jacobs,Hanna K. Sanoff,Deirdre Jill Cohen,Katherine A. Guthrie,Norah Lynn Henry,Patricia A. Ganz,Scott Kopetz,Peter C. Lucas,Charles D. Blanke,Norman Wolmark,Howard S. Hochster,Thomas J. George,Caio Max Sao Pedro Rocha Lima
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:39 (15_suppl): TPS3618-TPS3618 被引量:5
标识
DOI:10.1200/jco.2021.39.15_suppl.tps3618
摘要

TPS3618 Background: The superiority of inhibition of programmed cell death-1 (PD-1) pathway in dMMR/MSI-H over chemotherapy with either anti-vascular endothelial growth factor receptor (VEGFr) or anti- epithelial growth factor receptor (EGFr) antibodies in mCRC has been demonstrated in a phase III trial (N Engl J Med 2020; 383:2207). However, more patients had progressive disease as the best response in the anti-PD1 monotherapy arm (29.4% vs. 12.3%) with mean progression-free survival (PFS) of 13.7 months. Preclinical models have demonstrated synergistic interactions between FOLFOX, anti-VEGF, and anti-PD-1. We hypothesize that the dMMR/MSI-H mCRC patients may be more effectively treated by the combination of PD-1 pathway blockade and mFOLFOX6/bevacizumab (bev) rather than with anti-PD-L1 therapy (atezo) alone. Methods: Initially a three-arm study, the mFOLFOX6/bev arm was closed to new enrollment on 6-4-20 due to emerging data; the redesigned COMMIT trial was reactivated on 1/29/2021 as a prospective phase III open-label trial that randomizes (1:1) mCRC dMMR/MSI-H pts (N=211) to either atezo monotherapy or mFOLFOX6/bev+atezo combination. Stratification factors include BRAFV600E status, metastatic site, and prior adjuvant CRC therapy. Primary endpoint is PFS as assessed by site investigator. Secondary endpoints include overall survival (OS), objective response rate (RECIST v1.1), safety profile, disease control rate, duration of response, and centrally-reviewed PFS. Health-related quality of life is an exploratory objective. Archived tumor tissue and blood samples will be collected for correlative studies. Key inclusion criteria are: mCRC without prior chemotherapy for advanced disease; dMMR tumor determined by local CLIA-certified IHC assay (MLH1/MSH2/MSH6/PMS2) or MSI-H by local CLIA-certified PCR or NGS panel; and measurable disease per RECIST. Clinical trial: NCT02997228. Support: U10CA180868, -180822, -180888, -180819, UG1CA189867, U24CA196067; Genentech, Inc. Clinical trial information: NCT02997228.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xiaoyin完成签到 ,获得积分10
1秒前
2秒前
2秒前
Lifel完成签到,获得积分10
2秒前
9秒前
11秒前
A水暖五金批发张哥完成签到,获得积分10
11秒前
Ni完成签到 ,获得积分10
12秒前
云墨完成签到 ,获得积分10
12秒前
13秒前
椰子云发布了新的文献求助10
15秒前
学术雷锋发布了新的文献求助10
18秒前
Moon完成签到 ,获得积分10
22秒前
天真的乐驹完成签到 ,获得积分10
26秒前
李健的小迷弟的应助被郦稀采纳,获得10
26秒前
Moon关注了科研通微信公众号
26秒前
27秒前
乐康完成签到,获得积分10
27秒前
30秒前
复杂惜珊完成签到,获得积分10
37秒前
cx完成签到,获得积分10
42秒前
机灵伟诚完成签到,获得积分10
42秒前
学霸业的应助被纯情的阁采纳,获得10
44秒前
极限001的应助被纯情的阁采纳,获得50
44秒前
Maestro_S的应助被纯情的阁采纳,获得10
44秒前
Nikkie2411的应助被纯情的阁采纳,获得10
44秒前
47秒前
48秒前
369ninja的应助被科研通管家采纳,获得10
50秒前
丘比特的应助被科研通管家采纳,获得10
50秒前
手打鱼丸完成签到 ,获得积分10
50秒前
50秒前
完美世界的应助被科研通管家采纳,获得10
50秒前
莫名乐乐完成签到,获得积分10
50秒前
FashionBoy的应助被科研通管家采纳,获得10
50秒前
SciGPT的应助被科研通管家采纳,获得10
50秒前
Akim的应助被纯情的阁采纳,获得10
50秒前
null的应助被科研通管家采纳,获得10
50秒前
51秒前
隐形曼青的应助被纯情的阁采纳,获得10
51秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158598
求助须知:如何正确求助?哪些是违规求助? 9554358
关于积分的说明 21719087
捐赠科研通 7748128
什么是DOI,文献DOI怎么找? 3427032
关于科研通互助平台的介绍 2551902
邀请新用户注册赠送积分活动 2471277